For the year ending 2025-12-31, KOD had $41,788K increase in cash & cash equivalents over the period. -$136,514K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -229,967 |
| Depreciation | 18,328 |
| Stock-based compensation | 58,863 |
| Non-cash lease impairment expense | 1,910 |
| Net accretion of discount on marketable securities | 0 |
| Settlement of derivative contracts | 0 |
| Amortization of operating lease right-of-use asset | 7,992 |
| Adjustment to reconcile net income to cash provided by (used in) operating activity, other item | 20 |
| Prepaid expenses and other current assets | 891 |
| Other assets | -59 |
| Accounts payable | 8,070 |
| Accrued and other current liabilities | 9,273 |
| Operating lease liability | -11,165 |
| Long-term deposit | 1,500 |
| Net cash provided by (used in) operating activities | -136,008 |
| Purchase of property and equipment | 506 |
| Deposits on property and equipment | 0 |
| Purchase of marketable securities | 0 |
| Maturities of marketable securities | 0 |
| Settlement of derivative contracts | 0 |
| Net cash provided by (used in) investing activities | -506 |
| Proceeds from public offering, net of underwriting discount | 172,960 |
| Cash in-transit for stock option exercises | 5,162 |
| Proceeds from espp | 180 |
| Principal payments of tenant improvement allowance payable | 0 |
| Net cash provided by financing activities | 178,302 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 41,788 |
| Cash, cash equivalents and restricted cash, at beginning of period | 174,258 |
| Cash, cash equivalents and restricted cash, at end of period | 216,046 |
Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc. (KOD)